Creagene Inc.

Jw Pharmaceutical Corporation

Jw Creagene Inc.

Yong Soo Bae

Hyun Soo Lee

Jin Pil Kim

Dae Seog Lim

Kang Ryu

Eun Ju Kang

Young Hoon Kim

Hye Rhan Jung

Seung Ho Hong

Chan Kyu Lee

Jin Ah Jang

Seonyoung Yang

Seung Soo Han

The present invention relates to IFN-&#x3b1; fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN-&#x3b1; protein. The IFN-&#x3b1; fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the INF-&#x3b1; fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved. The IFN-&#x3b1; fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases, including various types of viral infections or the like.

Interferon-alpha fusion protein in which cytoplasmic transduction peptide and polyethylene glycol are bonded to one another

Disclosed is an interferon-&#x3b1; (IFN-&#x3b1;) fused protein having IFN-&#x3b1; fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-&#x3b1;, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.

Interferon-&#x3b1; (IFN-&#x3b1;) fused proteins comprising IFN-&#x3b1; and a cytoplasmic transduction peptide (CTP)

The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.

Use of MLN51 gene and protein

A replication-competent recombinant Sabin type 1 poliovirus vector containing a sequence coding for multiple cloning site and 3C-protease cleavage site is provided. This vector makes it easy to introduce various vaccine genes from infectious viruses to the Sabin 1 poliovirus, and facilitates to produce chimeric Sabin 1 polioviruses that are expected to be powerful oral mucosal vaccines against several infectious viral diseases.

Replication-competent recombinant Sabin type 1 strain of poliovirus

Growing community of inventors

Suwon-si, South Korea

Yong Soo Bae